Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03624231
Title Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Ulrich Keilholz
Indications

head and neck squamous cell carcinoma

Therapies

Durvalumab

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries DEU

Additional content available in CKB BOOST